Please login to the form below

Not currently logged in
Email:
Password:

Gilotrif

This page shows the latest Gilotrif news and features for those working in and with pharma, biotech and healthcare.

EMA starts firming up its stance on personalised medicines

EMA starts firming up its stance on personalised medicines

As more treatments like Pfizer’s Xalkori, Vertex’s Kalydeco and Boehringer Ingelheim’s Giotrif/Gilotrif come to market it also wants to better define those patients that will benefit from

Latest news

  • Boehringer stops Gilotrif head and neck cancer trials Boehringer stops Gilotrif head and neck cancer trials

    Boehringer Ingelheim has said it will abandon two trials of Gilotrif in head and neck cancer after disappointing data. ... Gilotrif (afatinib) has been on the market for EGFR-positive non-small cell lung cancer (NSCLC) for some time, and was recently

  • FDA approves expanded indication for Gilotrif FDA approves expanded indication for Gilotrif

    Boehringer Ingelheim has won US licensing for the expanded use of its EGFR-directed non-small cell lung cancer (NSCLC) drug Gilotrif. ... It showed Gilotrif achieved its primary objective of significantly improving progression-free survival when compared

  • Boehringer launches iPhone app for patients on Gilotrif Boehringer launches iPhone app for patients on Gilotrif

    More unusually though it also includes branded information about Gilotrif and on what to expect during treatment with the drug. ... Boehringer said at the time that it planned to support the Gilotrif's launch with a “comprehensive patient support

  • Opdivo gains new US lung cancer licence Opdivo gains new US lung cancer licence

    Current marketed therapies for NSCLC includes AstraZeneca's Iressa (gefitinib), Roche's Avastin (bevacizumab), as well as more recent treatments such as Pfizer's Xalkori (crizotinib) and Boehringer's Gilotrif (afatinib).

  • Boehringer’s Vargatef approved in the EU for lung cancer Boehringer’s Vargatef approved in the EU for lung cancer

    cancer.”. The launch of Giotrif/Gilotrif in 2013 as a treatment lung cancer patients who express epidermal growth factor receptor (EGFR) marked Boehringer's entry onto the oncology market.

More from news
Approximately 6 fully matching, plus 12 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Mind+Matter

We are Mind ‘PLUS’ Matter. The ‘plus’ is important to us because we are all about offering more for our...

Latest intelligence

01 PME-APR21 Cover.jpg
Virtual congresses: video thrilled the cardio tsar
Chris Ross explores the key learnings from a year of virtual congresses...
When Will We Be Back To Normal?
The definitive question of 2021, whether you’re a homeschooling parent, a homebound professional, a wanderer with nowhere to go… or all three at once....
How to tell your healthcare story.
Healthcare research is not a simple story and the people in charge of those moments need to be careful about the story that they tell....

Infographics